Integra LifeSciences (NASDAQ:IART) and Lyra Therapeutics (NASDAQ:LYRA) Head-To-Head Contrast

Integra LifeSciences (NASDAQ:IARTGet Rating) and Lyra Therapeutics (NASDAQ:LYRAGet Rating) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, dividends, earnings, valuation, institutional ownership, profitability and analyst recommendations.

Risk & Volatility

Integra LifeSciences has a beta of 1.14, suggesting that its stock price is 14% more volatile than the S&P 500. Comparatively, Lyra Therapeutics has a beta of -0.18, suggesting that its stock price is 118% less volatile than the S&P 500.


This table compares Integra LifeSciences and Lyra Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Integra LifeSciences 10.96% 16.93% 7.24%
Lyra Therapeutics N/A -84.26% -64.02%

Valuation & Earnings

This table compares Integra LifeSciences and Lyra Therapeutics’ gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Integra LifeSciences $1.54 billion 3.38 $169.07 million $1.98 31.66
Lyra Therapeutics $280,000.00 348.95 -$43.51 million ($3.35) -2.24

Integra LifeSciences has higher revenue and earnings than Lyra Therapeutics. Lyra Therapeutics is trading at a lower price-to-earnings ratio than Integra LifeSciences, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Integra LifeSciences and Lyra Therapeutics, as reported by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Integra LifeSciences 1 5 3 0 2.22
Lyra Therapeutics 0 0 1 0 3.00

Integra LifeSciences presently has a consensus price target of $75.50, indicating a potential upside of 20.45%. Given Integra LifeSciences’ higher probable upside, equities analysts plainly believe Integra LifeSciences is more favorable than Lyra Therapeutics.

Insider & Institutional Ownership

91.0% of Integra LifeSciences shares are owned by institutional investors. Comparatively, 51.1% of Lyra Therapeutics shares are owned by institutional investors. 4.2% of Integra LifeSciences shares are owned by company insiders. Comparatively, 16.4% of Lyra Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.


Integra LifeSciences beats Lyra Therapeutics on 10 of the 13 factors compared between the two stocks.

Integra LifeSciences Company Profile (Get Rating)

Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, and general surgery. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as asset management software and support, and after-market services. It also sells approximately 40,000 instrument patterns, and surgical and lighting products to hospitals and surgery centers, as well as dental, podiatry, and veterinary offices. In addition, the company provides regenerative technology products for the treatment of acute and chronic wounds; and surgical tissue repair products for hernia repair, peripheral nerve repair and protection, and tendon repair. Further, it offers skin and wound repair, plastics and surgical reconstruction products, bone grafts, and nerve and tendon repair products. The company offers its products directly through various sales forces and other distribution channels to the hospitals, integrated health networks, group purchasing organizations, clinicians, surgery centers, and health care providers in the United States, Europe, Asia Pacific, and internationally. Integra LifeSciences Holdings Corporation was incorporated in 1989 and is headquartered in Princeton, New Jersey.

Lyra Therapeutics Company Profile (Get Rating)

Lyra Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. The company's XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. Its product candidates include LYR-210, an anti-inflammatory implantable drug matrix for the treatment of chronic rhinosinusitis (CRS), which is in Phase II clinical trial; and LYR-220 for CRS patients with and without nasal polyps. The company was formerly known as 480 Biomedical, Inc. and changed its name to Lyra Therapeutics, Inc. in July 2018. Lyra Therapeutics, Inc. was incorporated in 2005 and is headquartered in Watertown, Massachusetts.

Receive News & Ratings for Integra LifeSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra LifeSciences and related companies with's FREE daily email newsletter.